Trial Details

Recruiting
Basic Information
Clinical ID c2177
Identifier IRCT20230511058153N1
Trial Title Comparison of the combined effect of mesalazine-crocin with mesalazine alone in the treatment of inflammatory bowel disease
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Condition 1: Crohn's disease. Condition 2: Ulcerative colitis. Crohn's disease [regional enteritis] Ulcerative colitis
Interventions Intervention 1: Intervention group: Standard treatment (Mesalazine tablet 1000 mg 3 times a day, Kimidaro Pharmaceutical Company) plus crocin capsule 15 mg (Darumed Pharmaceutical Company) twice a day for 8 weeks. Intervention 2: Control group: Standard treatment (mesalazine tablets 1000 mg 3 times a day, Kimidaro pharmaceutical company) plus placebo (in the form of crocin capsules and manufactured by the same Darumed pharmaceutical company) for 8 weeks.
Participant Information
Sponsor Shahre-kord University of Medical Sciences
City -
Country/Region Iran
Enrollment Criteria
Sex Requirement ALL
Age Requirement -
Study Design
Study Type interventional
Phase Not Available
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -